CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Goodwill Industries executive Keith Reissaus has been tapped to run Washington, D.C.-based Leapfrog Group, an industry coalition.
Reissaus gained control of health care costs by giving employees incentives to care about their health.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of
anti-psychotic drug Zyprexa.
The museum finally has a brand—it bills itself as a “center for science
and culture”—but don’t expect a splashy campaign.
The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage
by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just
about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.
Despite a vaguely worded veto threat by President Barack Obama, the House on Thursday easily adopted a major defense
policy bill that calls for continued development of a costly alternative engine for the Pentagon’s next-generation fighter
jet.
The recent slump in the domestic auto industry reminds us of the importance of innovation and creating something that will
be attractive to the consumer tomorrow. Companies that don’t foresee and adapt to the changing needs of their consumers
ultimately fail.
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
The measure holds potential bad news for Indianapolis engine maker Rolls-Royce because it does not contain funding for a key
jet engine the company produces, but lawmakers are expected to restore funding when the Senate and House combine bills into
a final version.
A city board this week will consider tax abatements worth about $47,000 over six years for Indianapolis-based IT consultant
Apparatus Inc., which is moving its headquarters to the former WFYI building at 1401 N. Meridian St.
Proposed changes to teacher licensing rules are a threat in the eyes of most deans of Indiana’s colleges of education—both
to the quality
of
teacher training and to the budgets of the colleges.
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
William J. Thomas has been named president of the Better Business Bureau of Central Indiana, the organization announced Monday.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
